Almirall (ALM) Panoramica del titolo
Almirall, S.A. opera come azienda biofarmaceutica incentrata sulla salute della pelle in Spagna, Europa, Medio Oriente, Stati Uniti, Asia e Africa. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 3/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ALM dai nostri controlli di rischio.
ALM Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Almirall, S.A.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €11.32 |
| Massimo di 52 settimane | €13.98 |
| Minimo di 52 settimane | €10.06 |
| Beta | 0.20 |
| Variazione di 1 mese | -11.01% |
| Variazione a 3 mesi | -15.65% |
| Variazione di 1 anno | 6.99% |
| Variazione a 3 anni | 35.98% |
| Variazione a 5 anni | -18.03% |
| Variazione dall'IPO | -24.53% |
Notizie e aggiornamenti recenti
Recent updates
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Rendimenti per gli azionisti
| ALM | ES Pharmaceuticals | ES Mercato | |
|---|---|---|---|
| 7D | -1.6% | -0.3% | 1.0% |
| 1Y | 7.0% | 10.6% | 22.7% |
Ritorno vs Industria: ALM ha avuto una performance inferiore rispetto al Spanish Pharmaceuticals che ha registrato un rendimento 10.6 % nell'ultimo anno.
Rendimento vs Mercato: ALM ha avuto una performance inferiore al mercato Spanish che ha registrato un rendimento 22.7 % nell'ultimo anno.
Volatilità dei prezzi
| ALM volatility | |
|---|---|
| ALM Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in ES Market | 6.7% |
| 10% least volatile stocks in ES Market | 0.9% |
Prezzo delle azioni stabile: ALM non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Spanish.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di ALM è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1943 | 2,108 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A. opera come azienda biofarmaceutica incentrata sulla salute della pelle in Spagna, Europa, Medio Oriente, Stati Uniti, Asia e Africa. L'azienda offre i suoi prodotti per le malattie della pelle, tra cui psoriasi, dermatite atopica, acne, cheratosi attinica, onicomicosi, alopecia androgenetica, oncodermatologia e indicazioni orfane, oltre che per il tratto alimentare e il metabolismo; antinfettivi per uso sistemico; sistema cardiovascolare, muscolo-scheletrico, nervoso e respiratorio; dermatologici; sistema genito-urinario e ormoni sessuali; immunostimolanti; metabolismo; e preparati ormonali sistematici. Ha una partnership multi-target con Etherna per la ricerca e lo sviluppo di terapie a base di mRNA per la dermatologia medica.
Almirall, S.A. Riepilogo dei fondamenti
| ALM statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €2.43b |
| Utili (TTM) | €39.85m |
| Ricavi(TTM) | €1.12b |
ALM è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ALM Conto economico (TTM) | |
|---|---|
| Ricavi | €1.12b |
| Costo del fatturato | €270.23m |
| Profitto lordo | €850.60m |
| Altre spese | €810.75m |
| Utili | €39.85m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Jul 24, 2026
| Utile per azione (EPS) | 0.19 |
| Margine lordo | 75.89% |
| Margine di profitto netto | 3.56% |
| Rapporto debito/patrimonio netto | 18.9% |
Come si è comportato ALM nel lungo periodo?
Vedi performance storica e confrontoDividendi
ALM paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ALM| Almirall date dei dividendi | |
|---|---|
| Data di stacco del dividendo | May 14 2026 |
| Data di pagamento dei dividendi | May 25 2026 |
| Giorni fino al dividendo Ex | 9 days |
| Giorni prima della data di pagamento dei dividendi | 2 days |
ALM paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ALMAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 15:19 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Almirall, S.A. è coperta da 27 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |